Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancerin vivoandin vitrothrough elevating p21 and ROS levels
Open Access
- 29 June 2014
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 5 (12) , 4567-4578
Abstract
Management of castration-resistant prostate cancer (CRPC) is challenging due to lack of efficacious therapy. Luteinizing hormone-releasing hormone (LHRH) analogs appear to act directly on cells based on the LHRH receptors on human prostate adenocarcinoma cells. We explored anticancer activity of a cytotoxic analog of LHRH, AEZS-108, consisting of LHRH agonist linked to doxorubicin. Nude mice bearing DU-145 tumors were used to compare antitumor effects of AEZS-108 with its individual constituents or their unconjugated combination. The tumor growth inhibition of conjugate was greatest among treatment groups (90.5% inhibition vs. 41% by [D-Lys(6)]LHRH+DOX). The presence of LHRH receptors on DU-145 cells was confirmed by immunocytochemistry. In vitro, AEZS-108 significantly inhibited cell proliferation (61.2% inhibition) and elevated apoptosis rates (by 46%). By the detection of the inherent doxorubicin fluorescence, unconjugated doxorubicin was seen in the nucleus; the conjugate was perinuclear and at cell membrane. Autophagy, visualized by GFP-tagged p62 reporter, was increased by AEZS-108 (7.9-fold vs. 5.3-fold by DOX+[D-Lys(6)]LHRH. AEZS-108 more effectively increased reactive oxygen species (ROS, 2-fold vs. 1.4-fold by DOX+[D-Lys(6)]LHRH) and levels of the apoptotic regulator p21 in vivo and in vitro. We demonstrate robust inhibitory effects of the targeted cytotoxic LHRH analog, AEZS-108, on LHRHR positive castration-resistant prostate cancer cells.Keywords
This publication has 72 references indexed in Scilit:
- An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancerOncoTargets and Therapy, 2013
- Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1eLife, 2012
- Experience with degarelix in the treatment of prostate cancerTherapeutic Advances in Urology, 2012
- Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinasesProceedings of the National Academy of Sciences, 2012
- Doxorubicin pathwaysPharmacogenetics and Genomics, 2011
- The Membrane-Bound Transcription Factor CREB3L1 Is Activated in Response to Virus Infection to Inhibit Proliferation of Virus-Infected CellsCell Host & Microbe, 2011
- Targeting DNA topoisomerase II in cancer chemotherapyNature Reviews Cancer, 2009
- Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2Free Radical Biology and Medicine, 2007
- Biologically active sphingolipids in cancer pathogenesis and treatmentNature Reviews Cancer, 2004
- A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicinBiochemical Pharmacology, 1999